Supplementary Material

Author(s): *David Mischoulon, MD, PhD; Andrew A. Nierenberg, MD; Pamela J. Schettler, PhD; Becky Kinkead, PhD; Kiki Fehling, BA; Max Martinson, BA; and Mark Hyman Rapaport, MD*

List of Supplementary Material for the article

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplemental Table 1
Current Anxiety Disorders in the Study Sample, and Change from Baseline to Treatment Week 8 for N=170 Evaluable Subjects[a]
Based on Mixed Model Repeated Measures Analysis[b]
For Groups Defined by Any vs. No Current Anxiety Diagnosis

Diagnosis		All Evaluable Subjects (N=170)[a]	EPA (N = 59)	DHA (N = 53)	Placebo (N = 58)	Significance		
						x^2	df	P
Current Anxiety Disorders								
Panic Disorder	N (%)	7 (4.1)	1 (1.7)	4 (7.6)	2 (3.4)	2.52[b]	2	0.283
Agoraphobia	N (%)	4 (2.4)	0 (0.0)	2 (3.8)	2 (3.4)	2.19[b]	2	0.334
Social Phobia	N (%)	16 (9.4)	5 (8.5)	7 (13.2)	4 (6.9)	1.39	2	0.500
Obsessive-Compulsive Disorder	N (%)	3 (1.8)	1 (1.7)	2 (3.8)	0 (0.0)	2.28[b]	2	0.320
Generalized Anxiety Disorder	N (%)	24 (14.1)	6 (10.2)	10 (18.9)	8 (13.8)	1.75	2	0.417
PTSD	N (%)	9 (5.3)	4 (6.8)	2 (3.8)	3 (5.2)	0.51[b]	2	0.776

Hamilton Depression Rating Scale - 17-Item Version (HAM-D$_{17}$) Analyzed by These Groups	Least-Square Means (se) of Change at Treatment Week 8[b]			Significance of Treatment-by-Time Interaction			Standardized Effect Size at Week 8[e]		
	EPA LS-Mean[c] (se) [N]	DHA LS-Mean[c] (se) [N]	Placebo LS-Mean[c] (se) [N]	F	df[d]	P	EPA vs. Placebo	DHA vs. Placebo	EPA vs. DHA
All Evaluable Subjects	- 10.34 (0.62) [60]	- 9.26 (0.62) [58]	- 9.49 (0.61) [59]	0.23	2, 687	0.794	- 0.179	+ 0.049	- 0.228
Current Anxiety Disorder[a]									
Yes	- 9.66 (1.08) [15]	- 9.81 (0.99) [17]	- 7.83 (1.19) [13]	0.72	2, 162	0.489	- 0.431	- 0.474	+ 0.036
No	- 10.68 (0.64) [44]	- 9.06 (0.70) [36]	- 9.80 (0.60) [45]	0.09	2, 575	0.916	- 0.213	+ 0.180	- 0.382

Hamilton Depression Rating Scale - 17-Item Version (HAM-D$_{17}$) by Current Anxiety Disorder[a]	Mean Baseline, Last Visit, and Change (Baseline to Last Visit)[f]			Significance of Treatment			

	EPA	DHA	Placebo	F	df	P
	[N] Mean (sd)	[N] Mean (sd)	[N] Mean (sd)			
Yes	[15]	[17]	[13]			
Baseline	21.20 (4.93)	20.35 (3.57)	19.15 (2.19)	1.02	2, 42	0.369
Last Visit	11.93 (5.57)	11.12 (4.76)	12.69 (7.51)	0.26	2, 42	0.770
Change (Baseline to Last Visit)	- 9.27 (6.60)	- 9.24 (5.78)	- 6.46 (7.15)	0.86	2, 42	0.431
No	[44]	[36]	[45]			
Baseline	18.45 (2.62)	19.58 (3.07)	19.16 (3.31)	1.45	2, 122	0.239
Last Visit	9.48 (6.58)	11.64 (6.49)	9.96 (5.08)	1.36	2, 122	0.261
Change (Baseline to Last Visit)	- 8.98 (6.91)	- 7.94 (6.34)	- 9.20 (5.52)	0.44	2, 122	0.644

Abbreviations: EPA: Eicosapentaenoic acid; DHA: docosahexaenoic acid; HAMD-17: 17-item Hamilton Depression Rating Scale; CGI: Clinical Global Improvement scale; se: standard error; df: degrees of freedom; PTSD: Post-Traumatic Stress Disorder.

a. N=7 subjects have no SCID data, so comorbid disorder information is missing.
b. HAM-D was administered at Baseline and at 2-week intervals during the 8-week study. A full-model MMRM was performed on change from Baseline to Week 8, testing the significance of effects of treatment, visit, and treatment-by-visit interaction, as well as the covariates of site, baseline score and baseline score-by-visit interaction.
c. Change at 8 weeks is significantly different from zero for each treatment group, by every breakdown of evaluable cases shown in the table, at $P \leq 0.001$.
d Degrees of freedom are determined using the Satterthwaite approximation method.
e. By Cohen's *d* effect size = (difference between LS-Mean change) / pooled sd for each pair of treatments (sd per group computed from se of LS-Mean from MMRM). A negative effect size indicates that the 1st group improved more than the 2nd one (has a lower negative LS-mean change).
f. Mean baseline, last visit, and change HAM-D scores by treatment group. NOTE: The last visit and change scores do not reflect time in treatment for subjects who terminated early.